Conversations in Drug Development Trends

FEBRUARY 21, 2024

We recently published a white paper discussing the value of proactive AME studies, best practices, and lessons we’ve learned over the years to help optimize your study. At Worldwide, our early phase team has conducted these studies for over 20 years, gaining invaluable experience and insights into best practices for an AME study.

Clinical Trials 80

Clinical Trials Pharmacy Clinical Pharmacology FDA 80

Conversations in Drug Development Trends

MARCH 20, 2024

In the increasingly advancing world of medicine, personalized care is a key factor that can progress your drug development efforts. As the study of how an individual’s genes affect their response to drugs, pharmacogenomics is a critical factor in developing effective and safe drugs and dosages in clinical trials.

Clinical Trials 52

Clinical Trials Trials Compliance Treatment 52

Conversations in Drug Development Trends

MARCH 7, 2024

When conducting first-in-human (FIH) clinical trials, small to midsize pharmaceutical and biotechnology companies are faced with several crucial choices that can shape the trajectory of their drug development pathway. For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.

Clinical Trials 52

Clinical Trials Trials FDA Drug Development 52

Drug Channels

MAY 20, 2021

Karen examines trends in drug development, pricing, and healthcare. To learn more, download Six trends and tactics to thrive in the new healthcare economy , a free white paper from Wolters Kluwer. She also serves as co-chair of Maintenance and Control at the NCPDP. Read on for Karen’s insights.

Drug Development 52

Drug Development Drugs 52

The Pharma Data

JANUARY 18, 2021

There is no way to eliminate the risk of failure. However, there are ways to reduce these risks. Learn more in this whitepaper from Recipharm. Source link.

Drug Development 52

Drug Development Drugs 52

PPD

JUNE 17, 2024

Often, however, a hybrid use case will fit into one of these general categories: 1) An existing FSO arrangement needs additional expertise or resources to support a specific study function, requiring the developer to scale or augment that FSO arrangement with FSP services.

Clinical Trials 52

Clinical Trials Clinical Development Trials International 52

Conversations in Drug Development Trends

NOVEMBER 21, 2023

In contrast, as a nonprofit organization, Every Cure can prioritize assets with the greatest opportunity for impact, filling the treatment gap that many traditional drug developers are not positioned to fill. To learn more about the Every Cure and Worldwide partnership, listen to a recent podcast episode between Dr.

Disease 78

Disease Treatment Clinical Trials Clinical Development 78

PPD

MARCH 21, 2024

When participating in clinical trials, pediatric populations require distinct considerations for their safety and well-being — which can present unique challenges for drug developers. A number of strategies can be adopted to put the needs of the child at the center of the study.

Clinical Trials 52

Clinical Trials Trials Drug Development Treatment 52

H1 Blog

AUGUST 10, 2023

To learn more about how Medical Affairs teams can leverage AI for smarter drug development, download our Custom White Paper with First Word Pharma: How AI Can Save Medical Affairs from Drowning in Data. Look for more content in our upcoming AI Content Hub.

Science 52

Science Drug Development Production Drugs 52

PerkinElmer

FEBRUARY 18, 2021

Eckelt conducted 23 hour-long, 1:1 interviews over five months in 2020 to gather market insights on how the top 20 Pharma are increasing productivity, efficiency, and speed of drug discovery in the short and long-term. A PerkinElmer White Paper offers a detailed look at the findings. It is an ongoing debate.

Biochemical Assays 52

Biochemical Assays Drugs Small Molecule Pharma Companies 52

PPD

DECEMBER 19, 2023

Ready to fuel more efficient drug development? Read our white paper to learn the keys to successfully implementing functional service partnerships. LEARN MORE The post Dedicated Roles Keep FSP Projects on Schedule appeared first on PPD Inc.

International 52

International Research Pharmaceuticals Drug Development 52

Conversations in Drug Development Trends

DECEMBER 20, 2023

You can learn more about biomarkers and how to use them in oncology studies in this white paper.

Clinical Trials 83

Clinical Trials Trials Pharmacokinetics FDA 83

Conversations in Drug Development Trends

MARCH 1, 2023

See how to unlock the full power of your CRO partner in our white paper, Optimal Outcomes in Clinical Research and Product Development. The post Transformational Relationships: How a Consultative Approach from a CRO Adds Value to Your Development Program appeared first on Worldwide Clinical Trials.

Clinical Research 52

Clinical Research Clinical Trials Science Trials 52

The Pharma Data

OCTOBER 16, 2020

We are in the process of finalizing arrangements with a global leader in drug development to assist in our development activities as we work toward a potential IND filing targeted in 2021.”. Download Medidata’s white paper to learn how to virtualize clinical trials and bring new therapies closer to patients.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. The workshop is also discussed in Cell & Gene here and here.

Therapies 59

Therapies Engineering Production FDA 59

The Pharma Data

DECEMBER 28, 2020

Dr. Russell has managed all aspects of the drug development and regulatory approval processes for oncology and non-oncology drug candidates. Mr. Weild authored and co-authored a number of definitive white papers that were key catalysts for new legislation and regulatory reforms, including the JOBS Act.

Pharmaceuticals 52

Pharmaceuticals Government Pharmaceutical Companies Therapies 52

The Pharma Data

SEPTEMBER 9, 2020

Receive expert-led insight from Dr. Heiner Oberkampf, Head of Data Governance at OSTHUS and learn how to: Digitally transform a drug development strategy. Develop a fully automated environment to significantly boost research efforts.

Production 52

Production Laboratories Compliance Government 52